DCM
VCYT icon

Delpha Capital Management’s Veracyte VCYT Stock Holding History

Delpha Capital Management’s Portfolio VCYT Stock Details VCYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-997
Closed -$7K – 1178
2017
Q4 		$7K Buy
+997
New +$7.41K 0.01% 1191

Other funds holding VCYT

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Delpha Capital Management's VCYT Position: Q1 2018 in Review

Delpha Capital Management sold out of Veracyte (VCYT) in Q1 2018, closing a stake of 997 shares — an estimated $7K sold.

Delpha Capital Management first reported a position in VCYT in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 80 funds tracked by Wall St. Rank hold VCYT as of Q1 2018.

  • Delpha Capital Management reported no remaining Veracyte position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 997 Veracyte shares in Q1 2018, an estimated $7K.
  • Delpha Capital Management first reported a position in Veracyte in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Veracyte position peaked at $7K in Q4 2017.
  • 80 funds tracked by Wall St. Rank held Veracyte as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.